Omega-3 And Alzheimer’S Risk — The Strongest Evidence We Have
Quick Read Omega-3 fatty acids, particularly two types called DHA and EPA found in fish and supplements, appear to play
We write a new article on supplements every day , all detailed, with citations.
Once a week we send an email containing a list of the last 7 days articles. Please sign up and also feel free to share the articles with friends and family who you think might benefit.
Simon Parrott – Vitacuity Ltd
When your body becomes resistant to insulin, your brain struggles too. Insulin normally helps brain cells absorb glucose for energy and clear out toxic proteins linked to Alzheimer’s disease. When insulin resistance develops, brain cells become starved for energy, become inflamed, and start to shrink. Research shows this “brain insulin resistance” is already damaging memory centres in people with prediabetes, years before cognitive problems become obvious.
Berberine, a compound from a traditional Chinese herb, appears to help reverse this damage in animal studies. It increases the number of insulin receptors on cells so they can respond to insulin better, activates energy-producing pathways in cells, reduces inflammation, and reshapes gut bacteria in ways that improve insulin sensitivity. In rats with diabetes or prediabetes, berberine improved memory and reduced brain damage as effectively as metformin, a standard diabetes drug.
The catch: nearly all evidence for berberine improving cognition comes from animal studies, not human trials. Human studies have confirmed berberine improves insulin sensitivity and blood sugar control, but large randomised trials specifically testing whether it prevents or reverses brain fog and cognitive decline don’t exist yet. The safety profile at typical doses (500 mg two to three times daily) is well-established.
Verdict: The science connecting insulin resistance to cognitive decline is solid, berberine’s mechanisms for improving insulin sensitivity are well-researched, but human evidence that it actually improves brain function remains preliminary.
What if the reason you can’t think clearly after lunch, or why your memory feels slower than it used to, isn’t tiredness, stress, or simply “getting older”, but something happening deep inside your brain cells, at the level of energy and signalling? What if the same metabolic process that leads to type 2 diabetes is quietly, years earlier, degrading the very circuits that make you sharp, focused, and quick? And what if a compound extracted from a traditional Chinese herb, studied for decades, might genuinely help reverse it?
This isn’t speculation dressed up in science. The research connecting insulin resistance to cognitive decline is serious, growing, and, frankly, underappreciated by most people outside academic medicine. Vitacuity reviewed over 1.77 million research papers and selected the most relevant studies on this topic. What follows is our honest, plain-English breakdown of what the evidence actually shows.
Most of us think of insulin as a blood sugar hormone, the thing your pancreas releases after you eat to shuttle glucose into your cells. That’s true. But insulin also plays a critical role in your brain. It supports neuron survival, regulates how your brain uses energy, and helps clear the toxic protein deposits, amyloid-beta and tau, that accumulate in Alzheimer’s disease.
When insulin resistance develops, as it does in tens of millions of people in their 40s and 50s, often without a formal diagnosis, it doesn’t just affect your muscles and liver. It reaches your brain [1].
Here’s the mechanism in plain English. Normally, insulin binds to insulin receptors on neurons, triggering a cascade of activity through signalling pathways called PI3K and AKT. These pathways tell neurons to absorb glucose (their primary fuel), protect themselves from damage, and clear out metabolic waste. When insulin resistance takes hold, this signalling cascade breaks down. The brain becomes less sensitive to insulin’s instructions. Neurons struggle to absorb glucose. Mitochondria, the tiny energy generators inside each cell, produce less ATP (cellular energy) and generate more damaging reactive oxygen species (ROS) instead [1].
The result? Brain cells are effectively starving for energy, even in a person who has plenty of glucose in their bloodstream. Mitochondrial function deteriorates. Neurons become inflamed. The brain’s ability to form and retrieve memories, particularly in the hippocampus, the region most associated with learning and memory, begins to decline [1].
Researchers have begun calling this state “Type 3 diabetes”, brain-specific insulin resistance, because its mechanisms so closely mirror what happens in systemic diabetes, and because its end-stage consequences overlap significantly with Alzheimer’s disease [1].
Evidence grade: Promising, one randomised controlled trial in 40 older adults, 40-week duration
A 2025 study published as a preprint, currently the most direct human evidence available, randomised 40 older adults with insulin resistance to either 40 weeks of metformin (an insulin-sensitising drug) or placebo [5]. The researchers weren’t just measuring blood sugar. They were measuring what was happening inside the brain.
The results were striking. Participants with greater insulin resistance showed reduced cerebral glucose uptake, meaning their brains were literally absorbing less energy fuel, alongside atrophy (shrinkage) and weakened connectivity between brain regions critical for cognition. These weren’t just statistical blips. They were measurable, structural changes in living human brains [5].
When insulin sensitivity was improved with metformin over 40 weeks, brain glucose uptake increased, cognitive network connectivity strengthened, and whole-brain volume was preserved, including in regions involved in decision-making and learning. Participants also showed improved processing speed and working memory [5].
This is the core insight: insulin resistance isn’t just a metabolic inconvenience. It’s actively degrading brain metabolism and structure, and reversing it appears to partially reverse those deficits [5]. The sample size is small (40 people), and this was a drug trial rather than a supplement trial, so we should be careful about overstating conclusions. But the mechanistic story it tells is consistent with everything else in the research.
Evidence grade: Early stage, primarily mechanistic and preclinical, with growing human observational data
One of the more troubling insights from recent research is that insulin resistance and neuroinflammation don’t just coexist, they amplify each other in a self-reinforcing loop [2].
Here’s how it works. Insulin resistance triggers the release of inflammatory cytokines, chemical signals of chronic, low-grade inflammation. Those cytokines then further disrupt insulin signalling in the brain, making insulin resistance worse. Which generates more inflammation. Which worsens insulin resistance further [2]. A 2025 mini-review in the *American Journal of Physiology-Endocrinology and Metabolism* described this as a “metabolic-inflammatory cycle”, and identified it as a key driver of cognitive decline and, in its most advanced form, Alzheimer’s disease [2].
The same paper noted that amyloid-beta plaques, the hallmark of Alzheimer’s, aren’t just a consequence of insulin resistance. They actively make things worse. A separate 2025 animal study found that amyloid-beta peptides block insulin’s entry into the brain by inhibiting the PI3K/AKT signalling pathway at the blood-brain barrier, the protective membrane separating the bloodstream from the brain [4]. In other words, once amyloid starts accumulating, it physically prevents insulin from reaching neurons, creating a vicious feedback loop [4].
This helps explain why Alzheimer’s and type 2 diabetes share so much pathological territory, and why managing metabolic health decades before dementia risk becomes apparent may matter enormously.
Evidence grade: Early stage, multiple well-designed animal studies, no large human RCTs yet for cognitive endpoints
Berberine is a yellow alkaloid compound found in several plants including *Coptis chinensis*, a herb used in traditional Chinese medicine for centuries. It’s been studied seriously in metabolic research for at least 15 years, and the findings on insulin sensitivity are consistent enough to be genuinely interesting.
In a 2021 animal study, researchers created a diabetes model in rats using a high-fat diet and a drug called streptozotocin, which induces metabolic dysfunction similar to type 2 diabetes [6]. These rats showed significant cognitive impairment, measurable on maze-learning tasks, alongside elevated amyloid-beta, phosphorylated tau protein, and hippocampal neuron damage. All of these are markers associated with Alzheimer’s-like pathology.
Berberine treatment significantly improved cognitive function in these animals. It reduced hippocampal tau protein and phosphorylated tau expression, reduced amyloid-beta deposition, and increased insulin receptor expression in the hippocampus, essentially helping neurons “hear” insulin’s signals again [6]. A TUNEL assay (a standard test for cell death) confirmed that berberine reduced hippocampal neuron apoptosis (programmed cell death) [6].
Critically, the researchers compared berberine to metformin, the standard pharmaceutical treatment for type 2 diabetes, and found comparable effects on both metabolic and cognitive parameters [6]. This comparison keeps appearing across berberine research, and it matters: it suggests the compound isn’t just mildly interesting but operates through similar and potent mechanistic pathways.
A separate 2021 cell and animal study explored the molecular mechanism more precisely [7]. It found that in neurons exposed to high glucose and high insulin conditions (mimicking the hyperinsulinaemia of insulin resistance), key insulin signalling proteins were disrupted. Berberine reversed these disruptions, increasing PI3K expression, improving glucose uptake via the GLUT3 transporter, and reducing the production of toxic amyloid-beta (Aβ42) fragments [7]. It also helped protect neuronal axons, the “wires” through which neurons communicate, from structural damage [7].
Evidence grade: Early stage, animal studies, mechanistic consistency across multiple papers
One of berberine’s most studied mechanisms is its activation of an enzyme called AMPK (AMP-activated protein kinase). Think of AMPK as a cellular energy sensor, it’s activated when cells are running low on ATP and need to switch into more efficient energy-producing mode. Exercise activates AMPK. Caloric restriction activates it. And so, apparently, does berberine [11].
A 2018 animal study in naturally ageing rats investigated whether berberine could improve both cognitive function and muscle performance, two functions that decline together in ageing and that share mitochondrial mechanisms [11]. Berberine activated the AMPK/SIRT1/PGC-1α pathway in skeletal muscle, a cascade that stimulates mitochondrial biogenesis (the creation of new mitochondria) and improves energy metabolism. Crucially, the animals also showed improved cognitive function on memory tasks [11].
This is important because it suggests berberine’s benefits aren’t limited to people with diagnosed diabetes. Insulin resistance and mitochondrial inefficiency are features of normal ageing, particularly from the mid-40s onwards, and a compound that addresses both simultaneously is genuinely interesting for healthy older adults, not just those with metabolic disease [11].
Evidence grade: Early stage, human cell line and animal studies
A foundational 2009 study published in *Metabolism* identified one of berberine’s most direct mechanisms: it increases the expression of insulin receptors themselves, the molecular “docking ports” on cell surfaces that allow insulin to deliver its signal [10].
In cultured human liver cells and rat skeletal muscle cells, berberine increased both the messenger RNA (the genetic instruction code) and the actual protein expression of insulin receptors in a dose- and time-dependent manner [10]. The mechanism involved activation of protein kinase C (PKC), which switches on the gene responsible for producing insulin receptors [10].
In animal models of type 2 diabetes, berberine treatment lowered fasting blood glucose and fasting insulin, increased insulin sensitivity, and elevated insulin receptor expression in the liver [10]. Importantly, berberine had no effect in type 1 diabetic mice (who lack insulin entirely), confirming it works by improving insulin signalling rather than stimulating insulin production, a meaningful mechanistic distinction [10].
This upregulation of insulin receptors is likely one of the core reasons berberine improves insulin sensitivity: it’s not just dampening a downstream signal but physically increasing the brain’s and body’s capacity to respond to insulin in the first place.
Evidence grade: Early stage, animal studies with mechanistic clarity
One of the more surprising findings in berberine research concerns the gut. A 2018 animal study found that a high-fat diet disrupted the gut microbiome in a specific way: it reduced populations of protective bacteria like *Bifidobacterium* and increased gram-negative bacteria like *Escherichia coli* [14]. Gram-negative bacteria release a molecule called lipopolysaccharide (LPS) when they die, and LPS entering the bloodstream triggers an inflammatory response via a receptor called TLR4.
This LPS/TLR4 pathway suppresses insulin receptor expression in the liver, directly causing insulin resistance [14]. Berberine treatment over 8 weeks (at 200 mg/kg in rats) reversed the microbiome disruption, reduced circulating LPS, and inhibited the TLR4/TNF-α inflammatory cascade, resulting in restored insulin receptor expression [14].
This gut-brain-metabolism connection is increasingly recognised in the research literature. A 2025 review specifically highlighted berberine’s modulation of the gut-brain axis as a mechanism through which it may protect against neuroinflammation and cognitive decline [2]. The gut isn’t just a digestive organ, it’s an active regulator of systemic and neurological inflammation, and berberine appears to work through this route as well as directly.
Evidence grade: Early stage, animal study, prediabetic model
Here’s something most people don’t realise: you don’t need a diabetes diagnosis for your brain to be affected by metabolic dysfunction. A 2024 animal study specifically examined prediabetes, a state of elevated blood sugar and insulin resistance that precedes a formal diagnosis and affects enormous numbers of people [9].
Prediabetic rats fed a high-fat diet for 20 weeks showed measurable cognitive impairment alongside elevated oxidative stress and apoptosis (cell death) in hippocampal tissue, before they had developed full diabetes [9]. When berberine was administered at 100 mg/kg for 7 weeks from week 13, blood glucose and lipid metabolism improved significantly. More importantly for our purposes, oxidative stress and apoptosis in hippocampal tissue were significantly reduced, and cognitive impairment was attenuated [9].
The implication is important: the window for intervention may be much earlier than most people assume. If you’re in your 40s or 50s with slightly elevated fasting glucose, climbing triglycerides, or energy crashes after meals, these may not be minor inconveniences but early signals of a metabolic process that, left unaddressed, begins affecting brain tissue.
This is where we owe you some honesty, and it matters.
Almost all the berberine-and-cognition research is in animals, not humans. The studies showing berberine improving hippocampal function, reducing tau and amyloid-beta, and reversing cognitive impairment were conducted in rats and mice [6][7][8][9][11]. Animal models are valuable, they allow controlled mechanistic investigation that isn’t possible in humans, but they don’t automatically translate. Many compounds that work brilliantly in rodents disappoint in human trials.
There are no large randomised controlled trials in humans specifically examining berberine’s effect on cognitive function. The human RCT in this field used metformin, not berberine [5]. Berberine’s insulin-sensitising effects in humans are reasonably well-evidenced for blood sugar and metabolic markers, but the cognitive endpoint is still extrapolated from animal data and mechanistic plausibility.
Berberine’s bioavailability is a known challenge. The compound is not particularly well absorbed from the gut in standard form, which complicates direct dose comparisons between animal and human studies. Newer formulations (such as berberine HCl with absorption enhancers) may perform differently, but this variable isn’t always accounted for in older research.
The “metabolic-inflammatory cycle” research is still largely mechanistic. While the logic of the cycle, insulin resistance driving inflammation, inflammation worsening insulin resistance, is well-supported in principle, the clinical trials needed to test whether breaking this cycle in humans meaningfully prevents cognitive decline haven’t been done yet [2].
Dosing and long-term safety in humans need more study. The animal studies use a range of doses (100–200 mg/kg in rats), which don’t translate directly to human equivalent doses. Human clinical trials for metabolic outcomes have typically used 500 mg two to three times daily, and found it generally well-tolerated, but long-term human safety data specifically for cognitive applications is limited.
We also note that the gut microbiome findings, while mechanistically compelling, are entirely from animal studies [14]. Whether berberine remodels the human gut microbiome in the same way, and whether that translates to reduced neuroinflammation, remains to be demonstrated in people.
Let’s reason through this honestly, the way a well-informed friend would.
The mechanistic case is strong and coherent: insulin resistance impairs brain energy metabolism, increases neuroinflammation, and, if sustained, contributes to the kind of structural brain changes associated with cognitive decline and dementia [1][5]. This isn’t fringe science. It’s increasingly mainstream.
Berberine addresses insulin resistance through multiple, well-characterised pathways, upregulating insulin receptors [10], activating AMPK [11], modulating gut microbiota [14], and reducing neuroinflammation [2][7]. In animal models, these effects translate meaningfully into improved hippocampal function and cognitive performance [6][8][9]. The comparison with metformin, a widely prescribed, well-studied drug, is consistent and encouraging [6].
What we can’t yet say is that berberine *will* improve your cognition or prevent dementia. The human trial data for that specific endpoint doesn’t yet exist. What we *can* say is that if you’re showing early signs of metabolic dysfunction, poor fasting glucose, insulin resistance, energy crashes, climbing waist circumference, this is worth taking seriously, and berberine is one of the more scientifically interesting tools available for addressing the underlying metabolic picture.
What a sensible, informed person might actually do:
1. Take the metabolic signals seriously early. Prediabetes-level insulin resistance is already damaging hippocampal tissue in animal models [9]. Don’t wait for a diagnosis, address the lifestyle foundations first: reducing refined carbohydrates, prioritising strength exercise (which activates AMPK independently), and improving sleep quality.
2. Consider berberine as a practical, low-risk supplement. At typical human doses of 500 mg two to three times daily with meals, berberine is generally well-tolerated and has a meaningful body of evidence for improving insulin sensitivity. It’s not a pharmaceutical, it won’t replace lifestyle changes, but as an adjunct, the risk-benefit profile is favourable. It’s not expensive, it’s widely available, and the safety profile at normal doses is well-established in the human metabolic literature.
3. Think of this as protecting a long-term asset. Cognitive decline typically takes decades to manifest. The time to support brain insulin sensitivity is not when symptoms are severe, it’s now, in your 40s and 50s, when the metabolic conditions that precede it are still modifiable.
4. Watch this space. Human RCTs examining berberine’s effects on cognitive outcomes in insulin-resistant adults are the logical next step, and given the mechanistic plausibility and the safety of the compound, they’re increasingly likely to happen. The science is moving quickly.
The bottom line: brain fog, sluggish memory, and cognitive fatigue in midlife may not be inevitable. Some of it appears to be metabolic, and metabolic problems, unlike ageing itself, can be meaningfully addressed. Berberine won’t fix a poor diet or a sedentary lifestyle. But as part of a serious approach to metabolic health, it’s one of the more interesting compounds the research currently supports.
[1] Brain insulin resistance mediated cognitive impairment and neurodegeneration: Type-3 diabetes or Alzheimer’s Disease (2025). https://pubmed.ncbi.nlm.nih.gov/39762668/
[2] Breaking the vicious cycle: bitter compounds targeting metabolic defects and inflammation in Alzheimer’s disease (2025). DOI: 10.1152/ajpendo.00166.2025 | https://pubmed.ncbi.nlm.nih.gov/40622910/
[3] Berberine: A Rising Star in the Management of Type 2 Diabetes-Novel Insights into Its Anti-Inflammatory, Metabolic, and Epigenetic Mechanisms (2025). DOI: 10.3390/ph18121890 | https://pubmed.ncbi.nlm.nih.gov/41471379/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12735998/
[4] Amyloid beta peptides inhibit brain insulin delivery via the blood-brain barrier (2025). DOI: 10.1002/alz70861_109020 | https://pubmed.ncbi.nlm.nih.gov/41433503/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12725453/
[5] Improvement in Insulin Sensitivity Prevents Decline in Glucose Uptake, Functional Connectivity, and Volume in the Insulin Resistant Human Brain (2025). DOI: 10.21203/rs.3.rs-7462946/v1 | https://pubmed.ncbi.nlm.nih.gov/40964018/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12440085/
[6] Effects of Berberine on Diabetes and Cognitive Impairment in an Animal Model: The Mechanisms of Action (2021). DOI: 10.1142/S0192415X21500658 | https://pubmed.ncbi.nlm.nih.gov/34137676/
[7] Berberine ameliorates neuronal AD-like change via activating Pi3k/PGCε pathway (2021). DOI: 10.1002/biof.1725 | https://pubmed.ncbi.nlm.nih.gov/33740285/
[8] Simulated weightlessness induces hippocampal insulin resistance and cognitive impairment (2023). DOI: 10.1016/j.lfs.2023.122112 | https://pubmed.ncbi.nlm.nih.gov/37758017/
[9] Berberine attenuates cognitive dysfunction and hippocampal apoptosis in rats with prediabetes (2024). https://pubmed.ncbi.nlm.nih.gov/38230770/
[10] Berberine reduces insulin resistance through protein kinase C-dependent up-regulation of insulin receptor expression (2009). https://pubmed.ncbi.nlm.nih.gov/19059538/
[11] Berberine Improves Cognitive Deficiency and Muscular Dysfunction via Activation of the AMPK/SIRT1/PGC-1a Pathway in Skeletal Muscle from Naturally Aging Rats (2018). https://pubmed.ncbi.nlm.nih.gov/29806860/
[14] Berberine Modulates Gut Microbiota and Reduces Insulin Resistance via the TLR4 Signaling Pathway (2018). https://pubmed.ncbi.nlm.nih.gov/29365334/
[15] A preliminary investigation of the mechanisms underlying the effect of berberine in preventing high-fat diet-induced insulin resistance in rats (2012). https://pubmed.ncbi.nlm.nih.gov/23211304/
This article is for informational purposes only and does not constitute medical advice. Food supplements should not be used as a substitute for a varied and balanced diet and healthy lifestyle. If you are pregnant, breastfeeding, taking medication or have a medical condition, consult your doctor before taking any supplement. These statements have not been evaluated by the Food and Drug Administration (FDA) or the Medicines and Healthcare products Regulatory Agency (MHRA). This product is not intended to diagnose, treat, cure, or prevent any disease.
Quick Read Omega-3 fatty acids, particularly two types called DHA and EPA found in fish and supplements, appear to play
Quick Read Vitamins are organic compounds your body cannot make enough of on its own. They act as molecular tools
Free guide: The research behind brain health supplements
Plus our weekly research digest — straight to your inbox.
Just leave your email address.
